articleThe LancetSep 5, 2019Closed access

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

BCBruce CreeJLJeffrey L. BennettHJHo Jin KimBGBrian G. WeinshenkerSJSean J Pittock

University of California, San Francisco · University of Colorado Anschutz Medical Campus · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

712
total citations
FWCI
50.80
Percentile
100%
References
26
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Medicine
  • Placebo
  • Population
  • Clinical endpoint
  • Neuromyelitis optica
  • Physical therapy
  • Clinical trial
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding